Paroxetine
Bipolar II Depression
Brigham and Women's HospitalSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Bipolar II Depression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Arestin University Health Network, Toronto | Phase 3 | BB |
Same molecule, other indications
Paroxetine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →